Anti-CD40 [chi220]
Catalogue Number: AB01685-2.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | TNFSF5; CDw40; TRAP; p50; Bp50; CD40L receptor; Tumor necrosis factor ligand superfamily member 5; B-cell surface antigen CD40; T-cell antigen Gp39; TNF-related activation protein. |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Mouse |
| Clone: | chi220 |
| Isotype: | IgG2a |
| Immunogen: | This antibody was generated by immunizing female BALB/c mice with a fusion protein containing extracellular domain of human CD40 fused to the hinge CH2 and CH3 domains of a murine IgG2b antibody. |
| Application: | Blk |
Additional Text
Uniprot ID
P29965
Gene Name
CD40LG
Gene ID
959
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Application Notes
This antibody blocks the interaction between CD40 and gp39. Chi220 was used either alone or in combination with CTLA4-Ig in an immunosuppresive therapy study to check the survival of renal allografts in non human primate models (PMID: 12394833). Chi220 blocks binding of CD154, it also has partial agonist properties and weak stimulatory potential. It synergisticaly works with LEA29Y (belatacept) to prolong the islet allograft survival in a non-human primate Macaca fascicularis (PMID: 15611281). A study on protection of islets xenographs in diabetic macaques used a combination of Chi220 with IL-2 receptor specific antibody Basiliximab for immunosuppression with induction therapy. Chi220 is used as an sCD154 blocking agent and it was seen that it binds sCD154 in a dose dependant manner (PMID: 21920020). Two humanized versions of this antibody were generated F4 and L3.17, also showed similar properties. Humanized versions of this antibody are available on request.
AB01685-2.0 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations